Maze Therapeutics (NASDAQ:MAZE) Reaches New 1-Year High – What’s Next?

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s stock price reached a new 52-week high during trading on Tuesday . The stock traded as high as $43.67 and last traded at $43.48, with a volume of 258852 shares. The stock had previously closed at $40.77.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a report on Wednesday, October 8th. HC Wainwright increased their price objective on Maze Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, December 3rd. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Guggenheim reiterated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research report on Friday, December 19th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $44.50.

Maze Therapeutics Trading Up 8.8%

The firm has a 50-day simple moving average of $38.91 and a two-hundred day simple moving average of $27.27. The company has a market capitalization of $2.13 billion and a price-to-earnings ratio of -2.12.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.08.

Insider Buying and Selling

In other news, SVP Amy Bachrodt sold 5,000 shares of the firm’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $39.15, for a total value of $195,750.00. Following the transaction, the senior vice president directly owned 12,965 shares of the company’s stock, valued at approximately $507,579.75. This trade represents a 27.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CMO Harold Bernstein sold 25,156 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $40.20, for a total transaction of $1,011,271.20. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 167,500 shares of company stock worth $6,774,667.

Hedge Funds Weigh In On Maze Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. purchased a new position in shares of Maze Therapeutics during the 1st quarter worth $145,000. Ensign Peak Advisors Inc acquired a new stake in Maze Therapeutics during the second quarter worth about $227,000. Frazier Life Sciences Management L.P. increased its position in Maze Therapeutics by 10.6% during the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock worth $56,040,000 after purchasing an additional 438,274 shares during the last quarter. Virtus Investment Advisers LLC purchased a new position in Maze Therapeutics during the second quarter worth about $85,000. Finally, CW Advisors LLC acquired a new position in Maze Therapeutics in the 2nd quarter valued at about $371,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.